Michael DiFiore
Stock Analyst at Evercore ISI
(0.69)
# 4,135
Out of 4,651 analysts
9
Total ratings
44.4%
Success rate
-10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $392 → $649 | $507.56 | +27.87% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $30.12 | +46.08% | 1 | Mar 12, 2026 | |
| ALT Altimmune | Initiated Coverage: Buy | $25 | $2.94 | +750.34% | 1 | Aug 22, 2025 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $0.5015 | n/a | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $98.66 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $8.09 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $16.33 | n/a | 1 | Sep 8, 2021 |
Madrigal Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $392 → $649
Current: $507.56
Upside: +27.87%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $30.12
Upside: +46.08%
Altimmune
Aug 22, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $2.94
Upside: +750.34%
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $0.5015
Upside: n/a
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $98.66
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $8.09
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $16.33
Upside: n/a